May 7th 2024
Early research suggests setanaxib combined with pembrolizumab may be a promising treatment for patients with squamous cell carcinoma of the head and neck.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Updated Findings Confirm Nivolumab OS Benefit in SCCHN
April 18th 2018Patients with metastatic or recurrent squamous cell carcinoma of the head and neck experienced a 32% reduction in the risk of death compared with investigator's choice of therapy, according to updated findings with a minimum of 2 years of follow-up from the phase III CheckMate-141 study.
Read More
FDA Places Hold on Axalimogene Filolisbac Plus Durvalumab Trial in Cervical, Head and Neck Cancer
March 14th 2018The FDA has placed a clinical hold on a phase I/II study of axalimogene filolisbac and durvalumab, according to an announcement by Advaxis, the manufacturer of axalimogene filolisbac, in a quarterly earnings report.The study is evaluating the combination in patients with advanced, recurrent or refractory HPV-associated cervical cancer and HPV-associated head and neck squamous cell carcinoma.
Read More